These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 30393007)

  • 1. Assessing genome-wide copy number aberrations and copy-neutral loss-of-heterozygosity as best practice: An evidence-based review from the Cancer Genomics Consortium working group for plasma cell disorders.
    Pugh TJ; Fink JM; Lu X; Mathew S; Murata-Collins J; Willem P; Fang M;
    Cancer Genet; 2018 Dec; 228-229():184-196. PubMed ID: 30393007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms.
    Kanagal-Shamanna R; Hodge JC; Tucker T; Shetty S; Yenamandra A; Dixon-McIver A; Bryke C; Huxley E; Lennon PA; Raca G; Xu X; Jeffries S; Quintero-Rivera F; Greipp PT; Slovak ML; Iqbal MA; Fang M
    Cancer Genet; 2018 Dec; 228-229():197-217. PubMed ID: 30377088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working group.
    Xu X; Bryke C; Sukhanova M; Huxley E; Dash DP; Dixon-Mciver A; Fang M; Griepp PT; Hodge JC; Iqbal A; Jeffries S; Kanagal-Shamanna R; Quintero-Rivera F; Shetty S; Slovak ML; Yenamandra A; Lennon PA; Raca G
    Cancer Genet; 2018 Dec; 228-229():218-235. PubMed ID: 30344013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing copy number aberrations and copy-neutral loss-of-heterozygosity across the genome as best practice: An evidence-based review from the Cancer Genomics Consortium (CGC) working group for chronic lymphocytic leukemia.
    Chun K; Wenger GD; Chaubey A; Dash DP; Kanagal-Shamanna R; Kantarci S; Kolhe R; Van Dyke DL; Wang L; Wolff DJ; Miron PM
    Cancer Genet; 2018 Dec; 228-229():236-250. PubMed ID: 30554732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignancies.
    Mukherjee S; Sathanoori M; Ma Z; Andreatta M; Lennon PA; Wheeler SR; Prescott JL; Coldren C; Casey T; Rietz H; Fasig K; Woodford R; Hartley T; Spence D; Donnelan W; Berdeja J; Flinn I; Kozyr N; Bouzyk M; Correll M; Ho H; Kravtsov V; Tunnel D; Chandra P
    Cancer Genet; 2017 Oct; 216-217():128-141. PubMed ID: 29025587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies.
    Ronaghy A; Yang RK; Khoury JD; Kanagal-Shamanna R
    Curr Hematol Malig Rep; 2020 Jun; 15(3):194-202. PubMed ID: 32382988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of cytogenomic microarray with plasma cell enrichment enables better abnormality detection and risk stratification in patients with plasma cell neoplasia than conventional cytogenetics and fluorescence in situ hybridization.
    Chen C; Lim AST; Lau LC; Lim TH; Heng EYH; Tien SL
    Cancer Genet; 2021 Apr; 252-253():25-36. PubMed ID: 33341677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
    Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
    Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter, cross-platform clinical validation study of cancer cytogenomic arrays.
    Li MM; Monzon FA; Biegel JA; Jobanputra V; Laffin JJ; Levy B; Leon A; Miron P; Rossi MR; Toruner G; Alvarez K; Doho G; Dougherty MJ; Hu X; Kash S; Streck D; Znoyko I; Hagenkord JM; Wolff DJ
    Cancer Genet; 2015 Nov; 208(11):525-36. PubMed ID: 26454669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk stratification of plasma cell neoplasm: insights from plasma cell-specific cytoplasmic immunoglobulin fluorescence in situ hybridization (cIg FISH) vs. conventional FISH.
    Dong H; Yang HS; Jagannath S; Stephenson CF; Brenholz P; Mazumder A; Chari A
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):366-74. PubMed ID: 22658896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optical Genome Mapping as a Next-Generation Cytogenomic Tool for Detection of Structural and Copy Number Variations for Prenatal Genomic Analyses.
    Sahajpal NS; Barseghyan H; Kolhe R; Hastie A; Chaubey A
    Genes (Basel); 2021 Mar; 12(3):. PubMed ID: 33799648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence-based review of genomic aberrations in B-lymphoblastic leukemia/lymphoma: Report from the cancer genomics consortium working group for lymphoblastic leukemia.
    Akkari YMN; Bruyere H; Hagelstrom RT; Kanagal-Shamanna R; Liu J; Luo M; Mikhail FM; Pitel BA; Raca G; Shago M; Shao L; Smith LR; Smolarek TA; Yenamandra A; Baughn LB
    Cancer Genet; 2020 May; 243():52-72. PubMed ID: 32302940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromosomal microarray analysis is superior in identifying cryptic aberrations in patients with acute lymphoblastic leukemia at diagnosis/relapse as a single assay.
    Chen C; Heng EYH; Lim AST; Lau LC; Lim TH; Wong GC; Tien SL
    Int J Lab Hematol; 2019 Aug; 41(4):561-571. PubMed ID: 31112375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Benchmarking of Optical Genome Mapping and Chromosomal Microarray Reveals High Technological Concordance in CNV Identification and Additional Structural Variant Refinement.
    Barseghyan H; Pang AWC; Clifford B; Serrano MA; Chaubey A; Hastie AR
    Genes (Basel); 2023 Sep; 14(10):. PubMed ID: 37895217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytogenetic Profile in Monoclonal Gammopathy of Undetermined Significance, Smoldering and Symptomatic Multiple Myeloma: A Study of 1087 Patients with Highly Purified Plasma Cells.
    Tang G; Wu Y; Lin P; Toruner GA; Hu S; Li S; Qazilbash MH; Orlowski RZ; Ye C; Xu J; Nahmod KA; Medeiros LJ; Tang Z
    Cancers (Basel); 2023 Dec; 15(23):. PubMed ID: 38067393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multimodal genomics approach to diagnostic evaluation of pediatric hematologic malignancies.
    Hiemenz MC; Oberley MJ; Doan A; Aye L; Ji J; Schmidt RJ; Biegel JA; Bhojwani D; Raca G
    Cancer Genet; 2021 Jun; 254-255():25-33. PubMed ID: 33571894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromosomal defects in multiple myeloma.
    Clarke SE; Fuller KA; Erber WN
    Blood Rev; 2024 Mar; 64():101168. PubMed ID: 38212176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analytical and clinical performance of chromosomal microarrays compared with FISH panel and conventional karyotyping in patients with chronic lymphocytic leukemia.
    Tang Z; Kanagal-Shamanna R; Tang G; Patel K; Medeiros LJ; Toruner GA
    Leuk Res; 2021 Sep; 108():106616. PubMed ID: 34022744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpG-stimulated chronic lymphocytic leukemia.
    Dubuc AM; Davids MS; Pulluqi M; Pulluqi O; Hoang K; Hernandez-Sánchez JM; Schlich C; Hernández-Rivas JM; Brown JR; Dal Cin P
    Am J Hematol; 2016 Oct; 91(10):978-83. PubMed ID: 27341486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Technical laboratory standards for interpretation and reporting of acquired copy-number abnormalities and copy-neutral loss of heterozygosity in neoplastic disorders: a joint consensus recommendation from the American College of Medical Genetics and Genomics (ACMG) and the Cancer Genomics Consortium (CGC).
    Mikhail FM; Biegel JA; Cooley LD; Dubuc AM; Hirsch B; Horner VL; Newman S; Shao L; Wolff DJ; Raca G
    Genet Med; 2019 Sep; 21(9):1903-1916. PubMed ID: 31138931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.